Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans.
Bramante S, Koski A, Kipar A, Diaconu I, Liikanen I, Hemminki O, Vassilev L, Parviainen S, Cerullo V, Pesonen SK, Oksanen M, Heiskanen R, Rouvinen-Lagerström N, Merisalo-Soikkeli M, Hakonen T, Joensuu T, Kanerva A, Pesonen S, Hemminki A. Bramante S, et al. Among authors: oksanen m. Int J Cancer. 2014 Aug 1;135(3):720-30. doi: 10.1002/ijc.28696. Epub 2014 Jan 10. Int J Cancer. 2014. PMID: 24374597
Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients.
Cerullo V, Pesonen S, Diaconu I, Escutenaire S, Arstila PT, Ugolini M, Nokisalmi P, Raki M, Laasonen L, Särkioja M, Rajecki M, Kangasniemi L, Guse K, Helminen A, Ahtiainen L, Ristimäki A, Räisänen-Sokolowski A, Haavisto E, Oksanen M, Karli E, Karioja-Kallio A, Holm SL, Kouri M, Joensuu T, Kanerva A, Hemminki A. Cerullo V, et al. Among authors: oksanen m. Cancer Res. 2010 Jun 1;70(11):4297-309. doi: 10.1158/0008-5472.CAN-09-3567. Epub 2010 May 18. Cancer Res. 2010. PMID: 20484030
Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors.
Nokisalmi P, Pesonen S, Escutenaire S, Särkioja M, Raki M, Cerullo V, Laasonen L, Alemany R, Rojas J, Cascallo M, Guse K, Rajecki M, Kangasniemi L, Haavisto E, Karioja-Kallio A, Hannuksela P, Oksanen M, Kanerva A, Joensuu T, Ahtiainen L, Hemminki A. Nokisalmi P, et al. Among authors: oksanen m. Clin Cancer Res. 2010 Jun 1;16(11):3035-43. doi: 10.1158/1078-0432.CCR-09-3167. Epub 2010 May 25. Clin Cancer Res. 2010. PMID: 20501623 Clinical Trial.
Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.
Koski A, Kangasniemi L, Escutenaire S, Pesonen S, Cerullo V, Diaconu I, Nokisalmi P, Raki M, Rajecki M, Guse K, Ranki T, Oksanen M, Holm SL, Haavisto E, Karioja-Kallio A, Laasonen L, Partanen K, Ugolini M, Helminen A, Karli E, Hannuksela P, Pesonen S, Joensuu T, Kanerva A, Hemminki A. Koski A, et al. Among authors: oksanen m. Mol Ther. 2010 Oct;18(10):1874-84. doi: 10.1038/mt.2010.161. Epub 2010 Jul 27. Mol Ther. 2010. PMID: 20664527 Free PMC article. Clinical Trial.
Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.
Pesonen S, Diaconu I, Cerullo V, Escutenaire S, Raki M, Kangasniemi L, Nokisalmi P, Dotti G, Guse K, Laasonen L, Partanen K, Karli E, Haavisto E, Oksanen M, Karioja-Kallio A, Hannuksela P, Holm SL, Kauppinen S, Joensuu T, Kanerva A, Hemminki A. Pesonen S, et al. Among authors: oksanen m. Int J Cancer. 2012 Apr 15;130(8):1937-47. doi: 10.1002/ijc.26216. Epub 2011 Aug 8. Int J Cancer. 2012. PMID: 21630267 Clinical Trial.
Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus.
Cerullo V, Diaconu I, Kangasniemi L, Rajecki M, Escutenaire S, Koski A, Romano V, Rouvinen N, Tuuminen T, Laasonen L, Partanen K, Kauppinen S, Joensuu T, Oksanen M, Holm SL, Haavisto E, Karioja-Kallio A, Kanerva A, Pesonen S, Arstila PT, Hemminki A. Cerullo V, et al. Among authors: oksanen m. Mol Ther. 2011 Sep;19(9):1737-46. doi: 10.1038/mt.2011.113. Epub 2011 Jun 14. Mol Ther. 2011. PMID: 21673660 Free PMC article. Clinical Trial.
Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients.
Pesonen S, Diaconu I, Kangasniemi L, Ranki T, Kanerva A, Pesonen SK, Gerdemann U, Leen AM, Kairemo K, Oksanen M, Haavisto E, Holm SL, Karioja-Kallio A, Kauppinen S, Partanen KP, Laasonen L, Joensuu T, Alanko T, Cerullo V, Hemminki A. Pesonen S, et al. Among authors: oksanen m. Cancer Res. 2012 Apr 1;72(7):1621-31. doi: 10.1158/0008-5472.CAN-11-3001. Epub 2012 Feb 9. Cancer Res. 2012. PMID: 22323527
Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus.
Kanerva A, Nokisalmi P, Diaconu I, Koski A, Cerullo V, Liikanen I, Tähtinen S, Oksanen M, Heiskanen R, Pesonen S, Joensuu T, Alanko T, Partanen K, Laasonen L, Kairemo K, Pesonen S, Kangasniemi L, Hemminki A. Kanerva A, et al. Among authors: oksanen m. Clin Cancer Res. 2013 May 15;19(10):2734-44. doi: 10.1158/1078-0432.CCR-12-2546. Epub 2013 Mar 14. Clin Cancer Res. 2013. PMID: 23493351 Clinical Trial.
Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients.
Liikanen I, Ahtiainen L, Hirvinen ML, Bramante S, Cerullo V, Nokisalmi P, Hemminki O, Diaconu I, Pesonen S, Koski A, Kangasniemi L, Pesonen SK, Oksanen M, Laasonen L, Partanen K, Joensuu T, Zhao F, Kanerva A, Hemminki A. Liikanen I, et al. Among authors: oksanen m. Mol Ther. 2013 Jun;21(6):1212-23. doi: 10.1038/mt.2013.51. Epub 2013 Apr 2. Mol Ther. 2013. PMID: 23546299 Free PMC article.
59 results